1,721,197 research outputs found
Time spent at home poststroke: “home-time” a meaningful and robust outcome measure for stroke trials
Full text link<p><b>Background and Purpose:</b> Stroke outcome assessment requires some measure of functional recovery. Several instruments are in common use but all have recognized limitations. We examined duration of stay in the patient’s own home over the first 90 days since stroke—"home-time"—as an alternative outcome likely to show graded response with improved reliability.</p>
<p><b>Methods:</b> We examined prospectively collected data from the GAIN International trial using analysis of variance with Bonferroni contrasts of adjacent modified Rankin scale score categories.</p>
<p><b>Results:</b> We had full outcome data from 1717 of 1788 patients. Increasing home-time was associated with improved modified Rankin scale scores (P<0.0001). The relationship held across all modified Rankin scale grades except 4 to 5.</p>
<p><b>Conclusions:</b> Home-time offers a robust, useful, and easily validated outcome measure for stroke, particularly across better recovery levels.</p>
Association of baseline blood lucose and outcome in patients treated with intravenous thrombolysis: results from SITS-ISTR.
No full textMarked increase in proportion of patients over 80 years treated with i.v. thrombolysis and registered in SITS /Safwe Implementtion of Treatments in Stroke) concides with publications.
No full textResults of Membrane-Activated Chelator Stroke Intervention randomized trial of DP-b99 in acute ischemic stroke.
No full textRelationship of blood pressure, antihypertensive therapy and outcome in ischaemic stroke treated with intravenous thrombolysis,. Retrospective analysis from Safe Implementation of Thrombolysis in Stroke – International stroke Thrombolysis register (SITS-ISTR).
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
An investigation of minimisation criteria
No full textMinimisation can be used within treatment trials to ensure that prognostic factors are evenly distributed between treatment groups. The technique is relatively straightforward to apply but does require running tallies of patient recruitments to be made and some simple calculations to be performed prior to each allocation. As computing facilities have become more widely available, minimisation has become a more feasible option for many. Although the technique has increased in popularity, the mode of application is often poorly reported and the choice of input parameters not justified in any logical way
Association of improved outcome in acute ischemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA
No full textBackground and purpose: Ischaemic stroke patients with atrial fibrillation
(AF) are at risk of early recurrent stroke (RS). However, antithrombotics
commenced at the acute stage may exacerbate haemorrhagic transformation,
provoking symptomatic intracerebral haemorrhage (SICH). The relevance of
antithrombotics on the patterns and outcome of the cohort was investigated.
Methods: A non-randomized cohort analysis was conducted using data
obtained from VISTA (Virtual International Stroke Trials Archive). The associations
of antithrombotics with the modified Rankin Scale (mRS) outcome
and the occurrence of RS and SICH (each as a combined end-point of fatal
and non-fatal events) at 90 days for post-stroke patients with AF were
described. Dichotomized outcomes were also considered as a secondary
end-point (i.e. mortality and good outcome measure at 90 days).
Results: In all, 1644 patients were identified; 1462 (89%) received antithrombotics,
157 (10%) had RS and 50 (3%) sustained SICH by day 90. Combined
antithrombotic therapy (i.e. anticoagulants and antiplatelets), 782 (48%), was
associated with favourable outcome on ordinal mRS and a significantly lower
risk of RS, SICH and mortality by day 90, compared with the no antithrombotics
group. The relative risk of RS and SICH appeared highest in the first
2 days post-stroke before attenuating to become constant over time.
Conclusions: The risks and benefits of antithrombotics in recent stroke
patients with AF appear to track together. Early introduction of anticoagulants
(2–3 days post-stroke), and to a lesser extent antiplatelet agents, was
associated with substantially fewer RS events over the following weeks but
with no excess risk of SICH. More evidence is required to guide clinicians on
this issue.Background and purposeIschaemic stroke patients with atrial fibrillation (AF) are at risk of early recurrent stroke (RS). However, antithrombotics commenced at the acute stage may exacerbate haemorrhagic transformation, provoking symptomatic intracerebral haemorrhage (SICH). The relevance of antithrombotics on the patterns and outcome of the cohort was investigated.MethodsA non-randomized cohort analysis was conducted using data obtained from VISTA (Virtual International Stroke Trials Archive). The associations of antithrombotics with the modified Rankin Scale (mRS) outcome and the occurrence of RS and SICH (each as a combined end-point of fatal and non-fatal events) at 90days for post-stroke patients with AF were described. Dichotomized outcomes were also considered as a secondary end-point (i.e. mortality and good outcome measure at 90days).ResultsIn all, 1644 patients were identified; 1462 (89%) received antithrombotics, 157 (10%) had RS and 50 (3%) sustained SICH by day 90. Combine..
- …
